Mga Batayang Estadistika
| CIK | 1191357 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Molecular Pharmacology (USA), Ltd.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| March 5, 2015 |
Molecular Pharmacology (USA) MLPH - FORM 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0167 Expires: March 31, 2015 Estimated average burden hours per response . . . . . 1.50 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXC |
|
| February 17, 2015 |
MLPH / Molecular Pharmacology (USA), Ltd. NT 10-Q - - MLPH - FORM 12B-25 - DECEMBER 31, 2014 OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response. |
|
| November 13, 2014 |
Molecular Pharmacology (USA) MLPH FORM 10-Q 09-30-2014 (Quarterly Report) OMB APPROVAL OMB APPROVAL OMB Number: 3235-0070 Expires: April 30, 2015 Estimated average burden hours per response: . |
|
| September 8, 2014 |
Molecular Pharmacology (USA) MLPH FORM 10-K - 06-30-2014 (Annual Report) OMB APPROVAL OMB Number: 3235-0063 Expires: April 30, 2015 Estimated average burden hours per response: ?????1,998. |
|
| May 6, 2014 |
Molecular Pharmacology (USA) MLPH FORM 10Q 03-31-2014 (Quarterly Report) OMB APPROVAL OMB Number: 3235-0070 Expires: April 30, 2015 Estimated average burden hours per response: . |
|
| July 19, 2013 |
Molecular Pharmacology (USA) Limited Molecular Pharmacology (USA) Limited Molecular Pharmacology (USA) Limited is pleased to advise that its wholly-owned subsidiary, Molecular Pharmacology Pty Ltd (MPL), an Australian company, has executed an agreement with a New York-based company, Dermatology Development Corporation (DDC) to develop and market a range of therapeutic, cosmetic and cosmecutical products based on the ThermaLIFE product range and its active ingredient. |
|
| July 19, 2013 |
OMB APPROVAL OMB Number: 3235-0060 Expires: April 30, 2015 Estimated average burden hours per response. |
|
| July 19, 2013 |
DERMATOLOGY DEVELOPMENT CORPORATION EX-10 2 agmjuly2013.htm MLPH AGREEMENT DERMATOLOGY DEVELOPMENT CORPORATION June 21, 2013 Molecular Pharmacology Pty Ltd Level 1, 284 Oxford Street LEEDERVILLE 6007 Western Australia Dear Michael, We wish to confirm an agreement between Dermatology Development Corporation (DDC), a corporation organized under the laws of the State of New York, and Molecular Pharmacology Pty Ltd (MPL). This contract |
